User profiles for Dany Anglicheau

Dany ANGLICHEAU

Departement of Nephrology and Kidney Transplantation, Necker Hospital
Verified email at aphp.fr
Cited by 13875

[HTML][HTML] Complement-binding anti-HLA antibodies and kidney-allograft survival

…, F Desgrandchamps, D Anglicheau… - … England Journal of …, 2013 - Mass Medical Soc
Background Anti-HLA antibodies hamper successful transplantation, and activation of the
complement cascade is involved in antibody-mediated rejection. We investigated whether the …

Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths

…, S Boucherit, B Coulibaly, D Anglicheau… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

S Caillard, D Anglicheau, M Matignon, A Durrbach… - Kidney international, 2020 - Elsevier
Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information
on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. …

MicroRNA expression profiles predictive of human renal allograft status

D Anglicheau, VK Sharma, R Ding… - Proceedings of the …, 2009 - National Acad Sciences
Immune rejection of organ transplants is a life-threatening complication and is exemplified
by alterations in the expression of protein-encoding genes. Because microRNAs (miRNAs) …

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

…, S Boucherit, D Anglicheau… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

D Anglicheau, P Laurent-Puig… - Journal of the …, 2003 - journals.lww.com
ABSTRACT. The immunosuppressive drug tacrolimus, whose pharmacokinetic characteristics
display large interindividual variations, is a substrate for P-glycoprotein (P-gp), the product …

Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes

D Joly, D Anglicheau, C Alberti… - Journal of the …, 2003 - journals.lww.com
ABSTRACT. The fate of octogenarians reaching end-stage renal disease (ESRD) is poorly
defined, and implicit dialysis rationing may be practiced in this age group. The main …

Antibody-mediated vascular rejection of kidney allografts: a population-based study

…, JP Duong-Van-Huyen, C Suberbielle, D Anglicheau… - The Lancet, 2013 - thelancet.com
Background Rejection of allografts has always been the major obstacle to transplantation
success. We aimed to improve characterisation of different kidney-allograft rejection …

Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

E Thervet, D Anglicheau, B King, MH Schlageter… - …, 2003 - journals.lww.com
Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is the …

Is COVID‐19 infection more severe in kidney transplant recipients?

…, A Durrbach, B Moulin, D Anglicheau… - American Journal of …, 2021 - Wiley Online Library
There are no studies which have compared the risk of severe COVID‐19 and related mortality
between transplant recipients and nontransplant patients. We enrolled two groups of …